

Angela D'Angelo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8621517/publications.pdf>

Version: 2024-02-01

120
papers

3,768
citations

147786

31
h-index

155644

55
g-index

130
all docs

130
docs citations

130
times ranked

4589
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1032-1037.	2.4	358
2	Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular Dementia. <i>Archives of Neurology</i> , 2005, 62, 1734.	4.5	195
3	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , 2021, 35, 1230-1236.	5.8	193
4	Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. <i>Journal of Hypertension</i> , 2005, 23, 1725-1729.	0.5	167
5	Matrix Metalloproteinase-2, -9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2006, 13, 227-231.	1.7	116
6	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 887-895.	3.4	102
7	Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study. <i>Inflammation</i> , 2013, 36, 914-920.	3.8	85
8	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 475-482.	3.1	84
9	Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor- α . <i>Hypertension Research</i> , 2006, 29, 849-856.	2.7	77
10	Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. <i>Atherosclerosis</i> , 2006, 186, 140-145.	0.8	67
11	Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial. <i>Clinical Therapeutics</i> , 2006, 28, 679-688.	2.5	66
12	HIGH LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS MAY BE A MARKER OF EXTREME LONGEVITY IN HUMANS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1149-1150.	2.6	63
13	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , 2007, 22, 361-370.	1.2	57
14	Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin. <i>Hypertension Research</i> , 2007, 30, 387-394.	2.7	56
15	A Clinical Trial about a Food Supplement Containing α -Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1802.	4.1	55
16	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , 2012, 6, 553-564.	1.5	52
17	<i>Berberis aristata</i> / <i>Silybum marianum</i> fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1495-1506.	3.1	50
18	Increased urinary NO 2 /NO 3 and cyclic guanosine monophosphate levels in patients with bartter's syndrome: Relationship to vascular reactivity. <i>American Journal of Kidney Diseases</i> , 1996, 27, 784-789.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010, 57, 777-786.	1.6	48
20	Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride. <i>Hypertension Research</i> , 2005, 28, 917-924.	2.7	47
21	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011, 651, 240-250.	3.5	47
22	Effects of nâ€³ pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , 2016, 42, 316-322.	5.4	47
23	Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. <i>Journal of Hypertension</i> , 2010, 28, 111-118.	0.5	44
24	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009, 24, 204-210.	1.2	41
25	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , 2018, 42, 75-82.	5.3	40
26	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 607-615.	1.9	38
27	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1973-1983.	1.9	37
28	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011, 34, 145-151.	2.7	36
29	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009, 32, 124.	0.6	36
30	Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients. <i>Internal Medicine</i> , 2010, 49, 1717-1725.	0.7	34
31	Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 421-429.	3.4	34
32	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , 2015, 239, 87-92.	0.8	33
33	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1971-1982.	1.8	32
34	Metalloproteinase-2 and -9 in Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007, 14, 45-51.	1.7	31
35	Comparison between orlistat plus <sc>l</sc>â€œcarnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 642-651.	1.9	30
36	Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin. <i>Internal Medicine</i> , 2013, 52, 2179-2187.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010, 80, 110-115.	2.5	29
38	Soluble RAGE Plasma Levels in Patients with Coronary Artery Disease and Peripheral Artery Disease. <i>Scientific World Journal</i> , The, 2013, 2013, 1-7.	2.1	29
39	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 329-335.	2.8	29
40	The role of a fixed <i>Berberis aristata</i> / <i>Silybum marianum</i> combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , 2016, 35, 1091-1095.	5.0	29
41	Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Atherosclerosis: Possible Correlation with Clinical Presentation. <i>Disease Markers</i> , 2013, 35, 135-140.	1.3	28
42	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 957-967.	3.4	28
43	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markers in the progression of diabetes in obese patients (The RESISTIN trial). <i>Cytokine</i> , 2020, 127, 154947.	3.2	27
44	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010, 33, 790-795.	2.7	26
45	Molecular Biology-Based Assessment of Vitamin E-Coated Dialyzer Effects on Oxidative Stress, Inflammation, and Vascular Remodeling. <i>Artificial Organs</i> , 2011, 35, E33-9.	1.9	26
46	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011, 113, 950-960.	1.5	26
47	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , 2010, 33, 209-213.	2.7	25
48	<i>Berberis aristata</i> / <i>Silybum marianum</i> fixed combination (Berberol [®]) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , 2015, 22, 231-237.	5.3	25
49	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010, 79, 144-149.	2.5	24
50	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2581-2591.	1.8	24
51	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , 2020, 73, 110700.	2.4	23
52	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2007, 29, 602-610.	2.5	22
53	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1059-1066.	3.4	22
54	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β -cell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2433-2442.	1.8	22

#	ARTICLE	IF	CITATIONS
55	Continuous Glucose Monitoring System in Free-Living Healthy Subjects: Results from a Pilot Study. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 159-169.	4.4	21
56	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 723-733.	5.6	21
57	<p>Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3647-3655.	4.3	21
58	Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naive Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial. <i>Internal Medicine</i> , 2007, 46, 1837-1846.	0.7	20
59	Longâ€Term Effects of a Multidisciplinary Treatment of Uncomplicated Obesity on Carotid Intimaâ€Media Thickness. <i>Obesity</i> , 2011, 19, 1187-1192.	3.0	20
60	<p>An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 653-661.	2.4	20
61	Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin. <i>Archives of Medical Research</i> , 2008, 39, 412-419.	3.3	19
62	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2017, 18, 343.	4.1	19
63	A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 214-222.	4.4	17
64	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , 2015, 100, 127-134.	7.1	17
65	<i>Ascophyllum nodosum</i> and <i>Fucus vesiculosus</i> on glycemic status and on endothelial damage markers in dysglycemic patients. <i>Phytotherapy Research</i> , 2019, 33, 791-797.	5.8	16
66	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , 2021, 8, 605691.	2.6	16
67	Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 357, 45-48.	2.1	15
68	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1113-1122.	1.6	15
69	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 66.	1.7	15
70	Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. <i>European Psychiatry</i> , 2006, 21, 129-133.	0.2	14
71	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1552-1557.	3.4	14
72	Lipoprotein(a)-Associated Atherothrombotic Risk in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2004, 24, 221-229.	3.1	13

#	ARTICLE	IF	CITATIONS
73	Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control in Patients with Impaired Glucose Tolerance. <i>Clinical Drug Investigation</i> , 2006, 26, 529-539.	2.2	13
74	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , 2015, 38, 690-694.	2.7	13
75	Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. <i>Clinica Chimica Acta</i> , 2004, 350, 159-165.	1.1	12
76	Metalloproteinases in Diabetics and Nondiabetics during Acute Coronary Syndromes and after 3 Months. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007, 14, 175-183.	1.7	12
77	Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine. <i>Internal Medicine</i> , 2009, 48, 265-271.	0.7	12
78	<p>Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1861-1865.	2.4	12
79	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 845-859.	1.5	12
80	Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. <i>International Journal of Molecular Medicine</i> , 2004, 13, 243-7.	4.0	12
81	Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010, 13, 378.	2.1	11
82	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012, 59, 611-619.	1.6	11
83	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , 2015, 766, 31-36.	3.5	11
84	Abscisic Acid Treatment in Patients with Prediabetes. <i>Nutrients</i> , 2020, 12, 2931.	4.1	11
85	<sc> <i>Ilex paraguariensis</i> </sc>, white mulberry and chromium picolinate in patients with preâ€diabetes. <i>Phytotherapy Research</i> , 2020, 34, 1377-1384.	5.8	11
86	The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1687, 1-10.	2.4	10
87	Effects of Insulin Therapy with Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Patients: Comparison with Multi-daily Insulin Injections Therapy (MDI). <i>Endocrine Journal</i> , 2009, 56, 571-578.	1.6	10
88	Diazepam as an oral hypnotic increases nocturnal blood pressure in the elderly. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 463-468.	2.9	10
89	Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 508-512.	1.9	9
90	Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT. <i>Mediators of Inflammation</i> , 2012, 2012, 1-6.	3.0	9

#	ARTICLE	IF	CITATIONS
91	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015, 14, 95.	6.8	9
92	Ambulatory 24-h ECG monitoring and cardiovascular autonomic assessment for the screening of silent myocardial ischemia in elderly type 2 diabetic hypertensive patients. <i>Heart and Vessels</i> , 2017, 32, 507-513.	1.2	9
93	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1391-1399.	2.0	9
94	<p>Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5367-5374.	4.3	9
95	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , 2009, 18, 111-116.	1.5	8
96	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , 2015, 47, 47-52.	3.8	8
97	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 582556.	4.8	8
98	Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients. <i>Clinical and Experimental Hypertension</i> , 2013, 35, 301-307.	1.3	7
99	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 621-629.	2.4	7
100	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placeboâ€Controlled Trial. <i>Pharmacotherapy</i> , 2015, 35, 983-990.	2.6	7
101	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 572.	4.1	7
102	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , 2017, 92, 75-79.	3.2	6
103	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , 2018, 233, 1791-1795.	4.1	6
104	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2611-2616.	4.3	6
105	Glycoâ€metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3219.	4.0	6
106	Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 12.	1.7	5
107	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , 2020, , 1-10.	1.5	5
108	Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study. <i>Biomedicines</i> , 2022, 10, 656.	3.2	5

#	ARTICLE	IF	CITATIONS
109	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , 2015, 5, 12603.	3.3	4
110	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , 2019, 11, 3075.	4.1	4
111	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 191-195.	1.4	4
112	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, <i>Vitis vinifera</i> L. and <i>Ginkgo biloba</i> , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction. <i>Frontiers in Endocrinology</i> , 2022, 13, 847240.	3.5	4
113	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1136-1141.	2.3	3
114	Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. <i>Archives of Medical Science</i> , 2017, 3, 550-557.	0.9	3
115	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , 2017, 14, 760-765.	0.9	2
116	Metabolic Actions of a Supplement of <i>Ilex Paraguariensis</i> (An Extract of the Leaf Standardized to 2%) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Dysglycemia: A Randomized Trial. <i>Life</i> , 2021, 11, 709.	2.4	2
117	Effects of a nutraceutical combination of monacolin, $\hat{1}^3$ -oryzanol and $\hat{1}^3$ -aminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , 2019, 15, 792-796.	0.9	2
118	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , 2019, 17, 1087-1092.	0.9	1
119	Detection of sieroic BAG3 in patients affected by cardiovascular diseases: State of art and perspectives. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 54-58.	2.6	1
120	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> , 0, , 70-78.	4.0	0